Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.

Keyphrases

• Desferrioxamine 100%
• Mesylate 100%
• Transfusional Iron Overload 100%
• Transfusion-dependent Thalassemia 100%
• Iron Chelator 25%
• Deferiprone 25%
• Placebo 20%
• Adverse Events 15%
• Iron Overload 15%
• Transfusion 10%
• Iron Chelation Therapy 10%
• Confidence Interval 5%
• Relative Risk 5%
• Data Extraction 5%
• To Determine the Effectiveness 5%
• Randomized Controlled Trial 5%
• Number of Deaths 5%
• Quality Assessment 5%
• MEDLINE 5%
• Embase 5%
• Route of Administration 5%
• Missing Data 5%
• Beneficial Effects 5%
• Treatment Group 5%
• Genetic Disease 5%
• Trial Quality 5%
• Anemia 5%
• Hemoglobin 5%
• Cochrane 5%
• Treatment Recommendations 5%
• Hemoglobinopathies 5%
• Current Control 5%
• Current Treatment 5%
• β-Thalassemia (β-thal) 5%
• Red Blood Cells 5%
• Methodological Quality 5%
• End-organ Damage 5%
• Reduced Iron 5%
• Optimal Schedule 5%
• Body Iron 5%

Nursing and Health Professions

• Thalassemia 100%
• Deferoxamine 100%
• Iron Poisoning 100%
• Deferoxamine Mesylate 100%
• Iron Chelating Agent 26%
• Deferiprone 26%
• Placebo 21%
• Adverse Event 15%
• Iron 15%
• Compliance 10%
• Chelation Therapy 10%
• Confidence Interval 5%
• Quality Control 5%
• Anemia 5%
• Data Extraction 5%
• Hemoglobinopathy 5%
• Genetic Disorder 5%
• Thalassemia Major 5%
• Treatment Group 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Thalassemia 100%
• Iron Poisoning 100%
• Deferoxamine 100%
• Deferoxamine Mesylate 100%
• Iron Chelating Agent 26%
• Deferiprone 26%
• Placebo 21%
• Adverse Event 15%
• Iron 15%
• Chelation Therapy 10%
• Randomized Controlled Trial 5%
• Anemia 5%
• Hemoglobinopathy 5%
• Thalassemia Major 5%
• Genetic Disorder 5%
• Treatment Group 5%